Analysis of large-cell lung cancer and its metastasis
Official title: Integrative Analysis of Large-cell Lung Carcinoma
Run by Shanghai 10th People's Hospital · NCT02917369 · Data updated 2026-11-12
This study is trying to understand large-cell lung cancer and how it spreads by comparing normal lung tissue to cancer samples, including those that have spread to the liver.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Shanghai 10th People's Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Ganzhou, Jiangxi and 2 other locations) |
| Status | Recruiting |
| Started | January 2016 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | September 28, 2016 |
| Trial ID | NCT02917369 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 75 years or younger with histologically confirmed large-cell lung cancer and a WHO performance status of 0 or 1.
✕Probably not a fit
Patients over the age of 75, those with severe major organ dysfunction, or those who have received prior cancer chemotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study conducts an integrative analysis of large-cell lung cancer (LCLC) by examining the proteomes of paired normal lung tissues and LCLC samples, both with and without liver metastasis. The methodology includes sequencing transcriptomes, whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets of normal lung tissue, primary LCLC carcinoma, and its matched metastasis. Additionally, the study will analyze genomic data from lung cancer previously characterized by The Cancer Genome Atlas (TCGA) to perform integrated proteogenomic analyses.
Why it matters
Potential benefit: If successful, this study could enhance understanding of LCLC and its metastasis, potentially leading to improved treatment strategies.
How similar studies have gone: Other studies utilizing integrative analyses of cancer genomics have shown promise, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≤ 75 years with histologically proven LCLC * No severe major organ dysfunction * World Health Organization (WHO) performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy
Where it's running
-
Ganzhou City People's Hospital
Ganzhou, Jiangxi, China Recruiting -
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China Recruiting -
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Principal investigator: Da Fu, PhD — Shanghai 10th People's Hospital
- Study coordinator: Da Fu, PhD
- Email: fu800da900@126.com
- Phone: 00-86-21-66301604
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.